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Abstract
Background
Studies of cancer prevalence have produced conflicting results concerning the relative risk
of overall and specific sub-types of cancer in patients with multiple sclerosis (MS). Contem-
porary controls and information on tobacco use and alcohol consumption are generally
missing from previous studies.
Objectives
To evaluate lifetime cancer prevalence in a large cohort of MS patients relative to appropri-
ate controls.
Methods
We conducted a case-control study, using a postal survey of a cohort of MS patients. Of the
1574 questionnaires sent, 1107 could be used for statistical analysis. Data from 1568 con-
trols were prospectively collected using the same self-administered survey among consecu-
tive out-patients in a single neurology department. Propensity scores matched on age,
gender, and history of smoking and alcohol consumption were calculated.
Results
Among the MS patients, 7.32% had ever presented with a cancer, whereas 12,63% of the
controls had, leading to a bootstrap matched odds ratio (OR) of 0.63; 95% CI 0.57–0.70.
Although only exploratory, the use of DMT (immunomodulators or immunosupressants) did
not appear to increase this risk (p = 0.42). The disease course also did not affect cancer
prevalence.
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Conclusion
MS was associated with a reduced overall cancer risk.
Introduction
The immune system plays an important role in both multiple sclerosis (MS) [1] and cancer
[2], making it plausible that cancer risk is modified by auto-immune diseases such as MS.
Some authors have hypothesized that some immunological characteristics of MS disease activ-
ity improve antitumor surveillance [3]. Others have proposed that disease modifying treat-
ments (DMT), especially immunosuppressive treatments (IS), could increase cancer incidence
in these patients [4,5]. Studies of cancer incidence and prevalence have produced conflicting
results concerning the relative risk of overall and specific sub-types of cancer in MS patients,
showing either a decreased or increased risk relative to the general population [6,7]. These
studies all have several weaknesses such as the lack of contemporary controls, the absence of
information concerning the two major cancer risk factors, tobacco use and alcohol consump-
tion, the potential role of DMTs, and the probable underestimation of cancer prevalence due
to incomplete reporting. Indeed, a recent meta-analysis calculated a global estimate of overall
cancer prevalence in MS of 4.39% that seems to be very low [6].
The primary objective of the present study was to evaluate lifetime cancer prevalence in a
large cohort of MS patients relative to contemporary controls coming from the same geo-
graphical area and matched for age, gender, history of tobacco use and alcohol consumption.
The secondary exploratory objectives were to assess the potential impact of DMTs on overall
cancer risk and to determine whether cancer prevalence was different between patients with
different disease courses.
Materials and methods
Subjects
The survey was conducted among the members of the “MS patients’ network in Auvergne”, an
administrative area in the centre of France. Patients can join this association only if their MS
diagnosis has been made by a neurologist whether they are followed in a hospital or by a pri-
vate neurologist. Patients with Clinically Isolated Syndrome (CIS) have been able to join the
association since 2013. A database was set-up with demographic and medical information con-
cerning the association members. According to the MS prevalence in Auvergne (1800 in
2013), this database contained 87% of MS patients from our catchment area (1,360,000 inhabi-
tants in 2013). The patients association database is approved by the National Commission of
Data Processing and Civil Liberties (CNIL), in accordance with French law. Controls were out-
patients visiting the Neurology Department of Clermont-Ferrand University Hospital and
their accompanying persons. The current study was approved by the appropriate Institutional
Review Board (Comite´ de Protection des Personnes Sud-Est 06, 2014/CE28).
Survey questionnaire
A self-administered questionnaire was sent to all 1574 members of the network in March
2014. The inclusion of consecutive outpatients seen in the Neurology department of the uni-
versity hospital and their accompanying person was carried out between August 2014 and
August 2015. This control population was selected as it was coming from the same catchment
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area as MS patients and was not receiving any immunomodulatory or immunosuppressant
treatments for chronic diseases. Moreover, there are no local or national cancer registries and
when available, such registries never contain informations about risk factors. Questionnaires
were secondarily anonymized and only one person (MP) had access to the corresponding list.
Both MS patients and controls had to respond to questions concerning their gender, date of
birth, history of cancer lesion, smoking history (daily use during at least one year), and history
of alcohol consumption (daily consumption during at least one year). We chose to be very sen-
sitive as even a low dose can promote cancer development. Patients with a history of cancer
also had to note the year of diagnosis, the implicated organ, and the name of their oncologist
or general practitioner to allow retrieval of the pathological confirmation of the cancer. To
limit the risk of cancer under-reporting, the question was “Have you ever had a cancer or a
cancerous lesion (in particular of the skin, cervix or cancerous intestinal polyp)?”. This ques-
tion was followed by a list of 22 potential cancer locations to make the reporting easier. MS
patients also had to include data concerning their inflammatory disease: type of disease (MS or
CIS), evolutive course of MS (relapsing-remitting (RR), secondary progressive (SP), primary
progressive (PP)), date of first MS signs, and name of DMT taken during at least three months.
Information declared by patients concerning MS was confirmed using the clinical database of
our hospital and the local European Database for Multiple Sclerosis [8] by the only person
who had access to the identity of the participants. People of the control group had only to state
the reason for their consultation or to note that they were an accompanying person. This infor-
mation was confirmed during the face to face interview. Face validity was tested on 10 healthy
volunteers and 10 patients. No other validation was performed on this simple home-made
questionnaire. For MS patients receiving the questionnaire and its accompanying letter, they
were free to participate or not to this survey. For these patients, sending the questionnaire
back was considered as a written consent to participate. Informed verbal consent was obtained
for every single person completing the questionnaire in the Neurology Department.
Patients consulting for a cancer-related neurological problem (mainly primary or second-
ary brain lesion and chemotherapy-induced peripheral neuropathy) were excluded.
The type of DMT was divided into four groups to allow statistical analysis: patients who
had received immunomodulatory therapies alone (IM), IS alone, both IM and IS, and those
who had never received any treatment. In the analyses of the impact of DMT, only cancers
that occurred after the first symptoms of MS, i.e. after the potential introduction of a DMT,
were taken into account.
CIS, RR-MS and SP-MS were grouped for the analysis of disease course, as they correspond
to three stages of the same form of the disease. PP-MS represented the other group.
Sample size calculation
To evaluate lifetime cancer prevalence in a large cohort of MS patients, the sample size estimation
was focused principally on the precision of the associated 95% confidence interval due to the lack
of precise data about the overall cancer prevalence in MS patients. Inclusion of more than 900
MS patients in the study allows a maximum margin of error of ±2% for a cancer prevalence of
between 5% and 15%. To evaluate the prevalence of MS patients relative to controls, the statistical
power to highlight an odds-ratio (OR) around 0.65, with a two-sided type I-error α of 5%, seemed
satisfactory (80%) with more than 900 subjects in each group (MS patients and controls) [9].
Statistical analysis
Statistical analysis was performed using Stata software (StataCorp LP, College Station, US). The
tests were two-sided, with α = 0.05. Subject characteristics are presented as the mean ± standard-
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error of the mean or median [interquartile range] for continuous data (assumption of normality
assessed using the Shapiro–Wilk test). Comparisons between groups were performed using chi-
squared or Fisher’s exact tests for categorical variables, and the Student t-test or Mann-Whitney
test for quantitative parameters (normality, homoscedasticity studied using the Fisher-Snedecor
test). Multivariate analysis was performed using generalized linear model (with logit link func-
tion for dichotomous dependent outcome). The covariates were retained according to univariate
results and to their clinical relevance. The covariates retained for multivariate analyses per-
formed to estimate the ORs for the impact of DMTs and impact of MS disease course were also
gender, age, alcohol and tobacco consumption. A particular focus was considered for the study
of interactions between factors and multicollinearity. Results were expresses as odds-ratios (OR)
and 95% confidence interval. As the baseline characteristics of MS patients differ from control
subjects, propensity score matching, defined by Rosenbaum and Rubin (1983), was performed.
The estimated propensity score is the predicted probability of group (MS or controls), derived
from the fitted regression model (logistic regression). As described by Austin [10], “stratification
on the propensity score involves stratifying subjects into mutually exclusive subsets based on
their estimated propensity score. Subjects are ranked according to their estimated propensity
score. Subjects are then stratified into subsets based on previously defined thresholds of the esti-
mated propensity score.” Therefore, when the propensity score has been correctly specified, the
distribution of measured baseline covariates will be approximately similar between cases and
controls within the same stratum. The covariates included in the propensity score model were
known to be clinically relevant and fixed according to univariate results: gender, age, alcohol and
tobacco consumption. As described for multivariate analyses, a particular attention was paid to
interactions and multicollinearity. Although there are different approaches to matching, the
most common approach in the medical literature is nearest neighbor pair matching without
replacement within specified calipers of the propensity score [11]. So, matchit command from
MatchIt package (R software) has been used to perform this analysis with a caliper width of 0.2.
Then, according to several recommendations, we have proposed an approach based on boot-
strap, a well-known resampling method for estimating the standard error of estimated statistics
and of constructing confidence intervals [12]. After bootstrap simulations (1000 simulations),
the odds ratio (OR) estimated for each randomly chosen group of patients were calculated and
are presented with the 95% confidence interval. As described by several authors [13], assessment
of residual confounding using sample-size independent tests, such as standardized differences,
has been proposed to evaluate the quality of treatment bias matching.
Results
Populations
Overall, 1111 out of the 1574 eligible MS patients responded to the survey, i.e. 70.6% of our
cohort. There was no difference in the average age of the responders and non-responders
(50.8 ± 0.4 vs 51.6 ± 0.6, p = 0.25), but the proportion of females was greater among responders
(79.2% vs 73.7%, p = 0.016). At the same time, 1590 consecutive non-MS outpatients or their
accompanying person were also included. These control subjects were not-included if they
were consulting for a problem related to a malignancy (for example epilepsia due to a cancer
lesion or chemotherapy-induced neuropathy). Among the 2701 subjects of the study, 26 (1%)
were not included in the analyses concerning demographic features, risk factors, and cancer
prevalence because of missing data or consultation due to a cancer. Finally, these analyses were
performed on data from 1107 MS patients and 1568 controls. MS patients were younger, more
likely to be female, and had a more frequent history of tobacco use. Alcohol consumption was
more frequent in non-MS patients (Table 1). Among the MS patients, 829 (75%) had a CIS,
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RR-MS or SP-MS and 76 (7%) had PP-MS. Information concerning the diagnosis was missing
for 202 patients (18%).
Overall lifetime cancer prevalence and the prevalence for specific
subtypes
In the MS group, 81 patients had had 84 cancers, three patients having had two, for an overall
cancer prevalence of 7.32%. The most frequent cancers were breast and skin cancers including
basal-cell carcinomas. In the control group, 198 subjects had had 214 cancers, 16 subjects hav-
ing had two for an overall cancer prevalence of 12,63%. The most frequent cancers were uro-
logical (with a majority being prostate cancer), breast, and skin cancers (Table 2). 11 patients
Table 1. Comparison of demographic characteristics and risks factors for cancer among patients with MS (n = 1107) and controls (n = 1568). SEM:
Standard error of the mean; MS: Multiple sclerosis.
Patients with MS
(n = 1107)
Controls
(n = 1575)
P
Age: mean ± SEM 50.7 ± 0.4 56.7 ± 0.5 <0.001
Female gender: % (n) 79.3 (878) 53.2 (834) <0.001
History of tobacco smoking: % (n) 49.8 (551) 42.8 (671) <0.001
History of alcohol drinking: % (n) 10.7 (118) 18.8 (294) <0.001
https://doi.org/10.1371/journal.pone.0188120.t001
Table 2. Overall lifetime cancer prevalence and specific subtypes of cancer prevalence in patients with MS (n = 1107) and controls (n = 1568).
Patients with MS
% (n)
Controls
% (n)
Patients with history of cancer 7.32 (81 patients, 84 cancers) 12.63 (198 patients, 214 cancers)
Breast cancers 2.53 (28) 2.42 (38)
Skin cancers
▪ Basal-cell carcinomas
▪ Squamous-cell carcinomas
▪Melanomas
▪Others skin cancers
1.36 (15)
▪ 0.90 (10)
▪ 0.00 (0)
▪ 0.36 (4)
▪ 0.09 (1)
2.04 (32)
▪ 1.21 (19)
▪ 0.06 (1)
▪ 0.64 (10)
▪ 0.13 (2)
Urological cancers
▪ Prostatic cancers
▪ Renal cancers
▪ Bladder cancers
▪ Testicular cancers
0.72 (8)
▪ 0.27 (3)
▪ 0.36 (4)
▪ 0.09 (1)
▪ 0.00 (0)
2.93 (46)
▪ 1.98 (31)
▪ 0.57 (9)
▪ 0.32 (5)
▪ 0.06 (1)
Gynecological cancers other than breast
▪Ovarian cancers
▪ Uterine cancers (cervical or endometrial)
1.17 (13)
▪ 0.09 (1)
▪ 1.08 (12)
1.79 (28)
▪ 0.45 (7)
▪ 1.34 (21)
Gastro-intestinal cancers
▪ Colorectal cancers
▪Oesophageal cancers
▪Gastric cancers
▪Others GI cancers
0.90 (10)
▪ 0.81 (9)
▪ 0.00 (0)
▪ 0.09 (1)
▪ 0.00 (0)
1.53 (24)
▪ 1.28 (20)
▪ 0.06 (1)
▪ 0.00 (0)
▪ 0.19 (3)
Brain tumors 0.00 (0) 0.13 (2)
Thyroid cancers 0.36 (4) 0.57 (9)
Hemopathies 0.36 (4) 1.02 (16)
Naso-pharyngeal cancers 0.18 (2) 0.57 (9)
Bronchopulmonary cancers 0.00 (0) 0.64 (10)
https://doi.org/10.1371/journal.pone.0188120.t002
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had declared a cancer that was not confirmed by pathology (5 in the MS group, 6 in the control
group).
Overall cancer prevalence after propensity score analysis and bootstrap
The propensity score matched on age, gender, and history of smoking and alcohol consump-
tion (Fig 1), allowing us to match 993 MS patients with 993 non-MS subjects, was performed
1000 times. The standardized difference for the four covariates was not significantly different
between MS patients and controls (S1 Fig). The mean OR was 0.63 (95% CI = 0.57–0.70) for
overall cancer prevalence (Fig 2).
Impact of DMTs
Data concerning treatments were available for 1089 MS patients (98.0%). The DMTs received
during at least three months are listed in Table 3. Among the MS patients, 61 had a history
of cancer after the first symptoms of MS (5.60%). Characteristics of the four treatment sub-
Fig 1. Propensity score distribution in MS patients and controls. Patients and controls were matched
using a propensity score with nearest neighbor pair matching without replacement within specified calipers
(width of 0.2). 1000 bootstrap simulations were then performed.
https://doi.org/10.1371/journal.pone.0188120.g001
Fig 2. Odds ratio estimates using bootstrap simulations (1000 randomly chosen group of patients
based on the propensity score model).
https://doi.org/10.1371/journal.pone.0188120.g002
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groups are presented in Table 4. Using multivariate analysis, patients who received treatment
had no greater risk of cancer than those who did not receive treatment (OR 1.22; 95% CI 0.63–
2.35; p = 0.55 for IM; OR 0.82; 95% CI 0.33–2.06; p = 0.67 for IS; and OR 0.78; 95% CI 0.33–
1.80; p = 0.55 for patients who had received at least one IM and one IS treatment).
Impact of MS disease course
The CIS, RR and SP-MS population was younger and with a higher proportion of women than
the PP-MS population. Tobacco use did not differ between the two sub-groups but alcohol
consumption was more frequent in the PP-MS group (Table 5). Multivariate analysis did not
find differences in cancer prevalence based on the course of the disease (OR 1.11; 95% CI
0.45–2.76; p = 0.818).
Discussion
This study assessed the life-time prevalence of cancer in MS patients and contemporary con-
trols, taking into account tobacco use and alcohol consumption. Our results show that there
was a decreased prevalence of overall cancer risk in patients with MS (OR: 0.63; 95 CI 0.57–
0.70) relative to matched subjects, despite use of DMTs.
Several previous studies have found a similar decreased cancer risk, in accordance with our
results. Kingwell and collaborators found a standardized incidence ratio (SIR) of cancer of
Table 3. Disease modifying treatments received for at least 3 months. IM: immunomodulatory disease
modifying treatments; IS: Immunosuppressant disease modifying treatments. The total is above 100% as
many patients have received more than one DMT during the time course of their disease.
% (n)
IM
▪ Interferon beta
▪Glatiramer Acetate
▪ Dimethyl fumarate
64.6 (703)
▪ 52.5 (572)
▪ 23.0 (250)
▪ 0.2 (2)
IS
▪ Fingolimod
▪ Natalizumab
▪Mitoxantrone
▪Methotrexate
▪ Azathioprine
▪ Cyclophosphamide
▪Mycophenolate Mofetil
▪ Teriflunomide
▪ Rituximab
31.8 (346)
▪ 4.3 (47)
▪ 10.2 (111)
▪ 4.0 (44)
▪ 9.6 (104)
▪ 5.1 (55)
▪ 4.3 (47)
▪ 3.4 (37)
▪ 0.1 (1)
▪ 0.1 (1)
None 24.8 (270)
https://doi.org/10.1371/journal.pone.0188120.t003
Table 4. Demographic characteristics, risk factors and overall cancer prevalence in different clusters of DMT. SEM: Standard error of the mean. IM:
immunomodulatory disease modifying treatments; IS: Immunosuppressant disease modifying treatments.
IM only
(n = 465)
IS only
(n = 114)
IM and IS
(n = 229)
None
(n = 264)
p
Age: mean ± SEM 47.1 ± 0.5 56.5 ± 1.2 49.0 ± 0.8 55.6 ± 0.8 <0.001
Female gender: % (n) 78.7 (366) 75.4 (86) 80.8 (185) 79.6 (210) 0.71
History of tobacco smoking: % (n) 53.6 (249) 38.6 (44) 52.8 (121) 46.6 (123) 0.02
History of alcohol consumption: % (n) 10.3 (48) 7.9 (9) 7.9 (18) 14.39 (38) 0.08
Overall cancer prevalence: % (n) 5.59 (26) 6.14 (7) 3.93 (9) 7.20 (19) 0.48
https://doi.org/10.1371/journal.pone.0188120.t004
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0.86 (95 CI 0.78–0.94) in a cohort study conducted in more than 6000 Canadian MS patients
[14]. Similar results have been obtained in France in a multicenter survey of 7418 MS patients
(SIR: 0.29; CI 95% 0.17–0.45 in men and 0.53; CI 95% 0,42–0,66 in women)[15]. This was con-
firmed in a recent meta-analysis [6]. However, other authors have reported no difference or an
increased risk of cancer prevalence in MS patients relative to the general population [6,7].
We present, for the first time, a prevalence estimate based on a large cohort of MS patients
compared to a contemporary control group matched for age, gender, tobacco use and alcohol
consumption, together with the impact of DMTs. Unlike previous studies based on cancer reg-
istries as a control group, we investigated the cancer risk in patients from the same geographic
area and have taken into account all cancer types, especially non-melanoma skin cancers that
were often excluded in registries. This under-reporting is highlighted by the results of a recent
meta-analysis that found an overall cancer prevalence in MS of 4.4%, far below the 7.3%
reported in the present study [6]. Another strength of our survey is that it is the first to take
into account two major risk factors for cancer (tobacco use and alcohol consumption).
Based on a recent meta-analysis, the risk of urinary system cancers appeared to be higher
than expected, whereas the risk of pancreatic, ovarian, prostate, and testicular cancer were
lower than expected [6]. In our cohort, we found the most frequent cancer type in MS patients
to be breast cancer, which would be expected in a population of middle-aged women. Evalua-
tion of the risk for each type of cancer was not possible in this study because of an insufficient
number of cancers of each type to allow sufficient statistical power for such an analysis.
We found no increased risk of cancer in patients who had received DMT, whether it was
IM or IS. Our results are in accordance with current knowledge concerning classical IM
[4,16]. Fewer studies have focused on the impact of IS on cancer risk in MS patients, as anti-
cancer treatments are well-known for inducing secondary neoplasms. Some studies suggest an
increased cancer risk for patients who received azathioprine, cyclophosphamide or several IS
[4], whereas another did not find any increased risk in patients receiving cyclophosphamide
[17]. Another study has recently shown that the overall incidence of malignancies was only
slightly increased in patients that had received mitoxantrone, but the risk of leukemia and
colorectal cancer was higher [5]. Notwithstanding, the cancer risk of such treatments is well-
known for indications in other inflammatory diseases [5,18]. Rheumatoid arthritis patients
receiving methotrexate have an increased risk of lymphoma, but it seems that this risk is linked
to the disease and not its treatment [19].
Anti-tumor immunosurveillance may provide the physiological explanation for the reduced
cancer-risk in MS patients [20,21]. Indeed, autoimmunity is a form of hyper-vigilance against
self-antigens, and may be one of the mechanisms leading to the development of MS. Further
studies are required to address this issue, for example, those investigating the properties of the
lymphocytes of MS-patients. It is noteworthy that several DMTs are also used, or are being
Table 5. Demographic characteristics, risk factors and overall cancer prevalence according to MS disease course. PP: Primary Progressive; RR:
Recurring Remitting; SP: Secondary Progressive; SEM: Standard error of the mean.
PP-MS
(n = 76)
CIS, RR-MS and SP-MS
(n = 829)
p
Age: mean ± SEM 57.8 ± 1.2 49.4 ± 0.4 <0.001
Female gender: % (n) 64.5 (49) 80.5 (667) 0.001
History of tobacco smoking: % (n) 40.8 (31) 51.3 (425) 0.08
History of alcohol consumption: % (n) 18.4 (14) 9.9 (82) 0.02
Overall cancer prevalence: % (n) 7.89 (6) 6.51 (54) 0.63
https://doi.org/10.1371/journal.pone.0188120.t005
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evaluated, for their potential anti-tumor activity. Examples include several DMTs such as
dimethyl fumarate, that induces necroptosis in colon cancer cells [22], fingolimod, that is
being tested on various cancers to increase the efficacy of other drugs, [23] and teriflunomide,
that has been shown to have anticancer activity against triple negative breast cancer cells [24].
Mitoxantrone is a well-known anti-neoplastic drug. Thus, DMTs may inhibit cancer develop-
ment in some cases, although they are used differently in oncology.
One limitation of our study stems from the restricted area in which it was conducted, lead-
ing to a number of cancer cases that is too small to obtain conclusions for each cancer sub-
type. Moreover, self-reporting of cancer can be seen as a bias, although the conditions to look
for cancer were the same in both patients and controls. Another limitation is that the study
was not powered to detect differences in cancer rates across DMT subgroups. Thus, although
these differences are non-significant, we cannot draw any firm conclusions. Moreover, the rel-
ative timing for DMT treatment and cancer is not precisely known. Careful monitoring of the
cancer risk related to these treatments will be still needed in the coming years, especially for
the newer ones. Data concerning the duration of DMT exposure are also lacking and must be
taken into account in future studies, as the cancer risk could be dose-dependent. A final limita-
tion concerns cancer risk factors. There is a lack of information concerning the intensity and
duration of alcohol consumption and tobacco use. Indeed, we had only binary data for the
presence or absence of daily alcohol consumption or tobacco use for at least one year during
the patients’ life. The impact of dose is well-known for these two factors and should have been
evaluated. Other risk factors should be explored in future studies (estrogen use, UV exposure,
nutritional habits, body mass index, viral infections,. . .).
In conclusion, MS was associated with a reduced overall cancer risk. Classical immuno-
modulator (beta-interferons and glatiramer acetate) and immunosuppressant use was not
associated with an increased overall cancer risk but there is not sufficient data to draw firm
conclusions. Concerning all these drugs and especially the newest, data from larger cohorts
and after longer exposure times is mandatory.
Supporting information
S1 Table. Reason for consultation of controls subjects.
(DOCX)
S1 Fig. Standardized difference for the 4 covariates (age, gender, history of smoking and
alcohol consumption) included in the 1000 bootstrap simulations. Using propensity score
matching, the distribution of observed baseline covariates (age, gender, and history of smoking
and alcohol consumption) was similar between controls and MS patients.
(TIFF)
S1 File. Competing_Interests_Statement.
(DOCX)
S2 File. Ethics_statement.
(DOCX)
S3 File. Survey questionnaire for patients with multiple sclerosis. Original version written
in French.
(DOCX)
S4 File. Survey questionnaire for patients with multiple sclerosis. Translated version written
in English.
(DOCX)
Cancer prevalence in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0188120 November 27, 2017 9 / 11
S5 File. Survey questionnaire for controls. Original version written in French.
(DOCX)
S6 File. Survey questionnaire for controls. Translated version written in English.
(DOCX)
Acknowledgments
We want to thank the “Re´seau Neuro-SEP Auvergne” and all the patients and controls.
Author Contributions
Conceptualization: Xavier Moisset, Maud Perie´, Bruno Pereira, Emilie Dumont, Frederic
Taithe, Pierre Clavelou.
Data curation: Xavier Moisset, Maud Perie´, Emilie Dumont, Franc¸ois-Xavier Lesage, Frederic
Dutheil, Frederic Taithe, Pierre Clavelou.
Formal analysis: Bruno Pereira.
Funding acquisition: Pierre Clavelou.
Investigation: Xavier Moisset, Maud Perie´, Bruno Pereira, Emilie Dumont, Frederic Taithe,
Pierre Clavelou.
Methodology: Xavier Moisset, Maud Perie´, Bruno Pereira, Pierre Clavelou.
Project administration: Xavier Moisset, Maud Perie´, Pierre Clavelou.
Resources: Xavier Moisset, Maud Perie´, Bruno Pereira, Emilie Dumont, Franc¸ois-Xavier
Lesage, Frederic Dutheil, Frederic Taithe, Pierre Clavelou.
Supervision: Xavier Moisset, Maud Perie´, Pierre Clavelou.
Validation: Xavier Moisset, Maud Perie´, Bruno Pereira, Emilie Dumont, Christine Lebrun-
Frenay, Franc¸ois-Xavier Lesage, Frederic Dutheil, Frederic Taithe, Pierre Clavelou.
Visualization: Xavier Moisset, Maud Perie´, Bruno Pereira, Emilie Dumont, Franc¸ois-Xavier
Lesage, Frederic Dutheil, Frederic Taithe, Pierre Clavelou.
Writing – original draft: Xavier Moisset, Maud Perie´.
Writing – review & editing: Xavier Moisset, Maud Perie´, Bruno Pereira, Emilie Dumont,
Franc¸ois-Xavier Lesage, Frederic Dutheil, Frederic Taithe, Pierre Clavelou.
References
1. Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis.
Curr Opin Neurol. 2015; 28: 206–219. https://doi.org/10.1097/WCO.0000000000000205 PMID:
25887768
2. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in can-
cer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012; 23 Suppl 8: viii6–9. https://doi.org/10.1093/
annonc/mds256 PMID: 22918931
3. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple
sclerosis and their parents. Neurology. 2009; 72: 1170–1177. https://doi.org/10.1212/01.wnl.
0000345366.10455.62 PMID: 19332695
4. Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, et al. Cancer and multiple sclero-
sis in the era of disease-modifying treatments. J Neurol. 2011; 258: 1304–1311. https://doi.org/10.1007/
s00415-011-5929-9 PMID: 21293872
Cancer prevalence in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0188120 November 27, 2017 10 / 11
5. Buttmann M, Seuffert L, Ma¨der U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis: A
retrospective cohort study. Neurology. 2016; https://doi.org/10.1212/WNL.0000000000002745 PMID:
27170571
6. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. A systematic review of the inci-
dence and prevalence of cancer in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2015;
21: 294–304. https://doi.org/10.1177/1352458514564489 PMID: 25533302
7. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease,
multiple sclerosis and Parkinson’s disease: record linkage studies. J Neurol Neurosurg Psychiatry.
2010; 81: 215–221. https://doi.org/10.1136/jnnp.2009.175463 PMID: 19726405
8. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European data-
base for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992; 55: 671–676. PMID: 1527537
9. Machin D, Campbell MJ, Tan S-B, Tan S-H. Sample Size Tables for Clinical Studies. John Wiley &
Sons; 2011.
10. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in
Observational Studies. Multivar Behav Res. 2011; 46: 399–424. https://doi.org/10.1080/00273171.
2011.568786 PMID: 21818162
11. Austin PC. The relative ability of different propensity score methods to balance measured covariates
between treated and untreated subjects in observational studies. Med Decis Mak Int J Soc Med Decis
Mak. 2009; 29: 661–677. https://doi.org/10.1177/0272989X09341755 PMID: 19684288
12. Austin PC, Small DS. The use of bootstrapping when using propensity-score matching without replace-
ment: a simulation study. Stat Med. 2014; 33: 4306–4319. https://doi.org/10.1002/sim.6276 PMID:
25087884
13. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment
groups in propensity-score matched samples. Stat Med. 2009; 28: 3083–3107. https://doi.org/10.1002/
sim.3697 PMID: 19757444
14. Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, et al. Cancer risk in multiple sclerosis: find-
ings from British Columbia, Canada. Brain J Neurol. 2012; 135: 2973–2979. https://doi.org/10.1093/
brain/aws148 PMID: 22730559
15. Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, et al. Cancer risk and
impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler Houndmills
Basingstoke Engl. 2008; 14: 399–405. https://doi.org/10.1177/1352458507083625 PMID: 18420778
16. Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with β-inter-
feron treatment for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014; 85: 1096–1102. https://doi.
org/10.1136/jnnp-2013-307238 PMID: 24594506
17. Le Bouc R, Ze´phir H, Majed B, Ve´rier A, Marcel M, Vermersch P. No increase in cancer incidence
detected after cyclophosphamide in a French cohort of patients with progressive multiple sclerosis. Mult
Scler Houndmills Basingstoke Engl. 2012; 18: 55–63. https://doi.org/10.1177/1352458511416839
PMID: 21844065
18. Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophospha-
mide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010; 62: 9–21.
https://doi.org/10.1002/art.25061 PMID: 20039416
19. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, et al. Lymphomas in rheu-
matoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;
99: 3909–3915. PMID: 12010788
20. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007; 117: 1137–1146. https://doi.
org/10.1172/JCI31405 PMID: 17476343
21. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer.
Annu Rev Immunol. 2011; 29: 235–271. https://doi.org/10.1146/annurev-immunol-031210-101324
PMID: 21219185
22. Xie X, Zhao Y, Ma C-Y, Xu X-M, Zhang Y-Q, Wang C-G, et al. Dimethyl fumarate induces necroptosis
in colon cancer cells through glutathione depletion/ROS increase/MAPKs activation pathway. Br J Phar-
macol. 2015; https://doi.org/10.1111/bph.13184 PMID: 25953698
23. White C, Alshaker H, Cooper C, Winkler M, Pchejetski D. The emerging role of FTY720 (Fingolimod) in
cancer treatment. Oncotarget. 2016; https://doi.org/10.18632/oncotarget.7145 PMID: 27036015
24. Huang O, Zhang W, Zhi Q, Xue X, Liu H, Shen D, et al. Teriflunomide, an immunomodulatory drug,
exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med Maywood NJ. 2015; 240:
426–437. https://doi.org/10.1177/1535370214554881 PMID: 25304315
Cancer prevalence in multiple sclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0188120 November 27, 2017 11 / 11
